Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$34.25 USD
+0.75 (2.24%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $34.39 +0.14 (0.41%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRBP 34.25 +0.75(2.24%)
Will CRBP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging HealthEquity (HQY) This Year?
Other News for CRBP
Marijuana Stock Movers For April 25, 2024
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market
Cannabis Stock Movers For April 22, 2024
Biotech Alert: Searches spiking for these stocks today